Total biopharma financings for the first four months of 2025 reached $15.48 billion, a 71% decline from $53.49 billion in ...

The use of mimicking antibodies that activate death receptors (DRs) to selectively induce cell death in cancer cells has ...

Among three Korean biotech companies slated to sell shares on the Korea Exchange this month, Immuneoncia Therapeutics Inc. is ...

Sen. Amy Klobuchar (D-Minn.) spoke to an industry meeting in Washington and expressed concerns about the situation at the U.S ...

The U.S. Department of Justice may have dismantled its civil division, but that doesn’t mean companies in the life sciences can let their guard down.

Raythera Inc. has described C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, ...

Triple-negative breast cancer (TNBC), which accounts for up to 20% of cases of breast cancer, is one of the most aggressive and difficult to treat subtypes of the disease.

Viromed Medical AG recently signed a couple of deals to get its devices based on cold plasma technology into the hands of clinicians to treat patients with skin diseases and pneumological infections.

The transcriptional repressor B-cell lymphoma 6 (BCL6) plays a central role in the development and progression of various B-cell malignancies, particularly diffuse large B-cell lymphoma (DLBCL), where ...

Breast cancer was the second most frequent cause of new cancer cases worldwide in 2024, and up to 20% of cases fall under the subtype of triple-negative breast cancer (TNBC), one of the most ...

Obi Pharma Inc. has gained IND clearance from the FDA for OBI-902, a TROP2-targeting cancer therapy for advanced solid tumors.

BLR Bio LLC has announced new data on BLR-200, its lead compound for systemic sclerosis and lung fibrosis. In the new study, BLR-200 demonstrated the ability to reduce key disease tissue markers for ...